These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 14726411

  • 1. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.
    Flood C, Gustafsson M, Pitas RE, Arnaboldi L, Walzem RL, Borén J.
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):564-70. PubMed ID: 14726411
    [Abstract] [Full Text] [Related]

  • 2. Identification of the proteoglycan binding site in apolipoprotein B48.
    Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Borén J.
    J Biol Chem; 2002 Aug 30; 277(35):32228-33. PubMed ID: 12070165
    [Abstract] [Full Text] [Related]

  • 3. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.
    Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL.
    J Clin Invest; 1998 Jun 15; 101(12):2658-64. PubMed ID: 9637699
    [Abstract] [Full Text] [Related]

  • 4. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.
    Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Borén J.
    Nature; 2002 Jun 13; 417(6890):750-4. PubMed ID: 12066187
    [Abstract] [Full Text] [Related]

  • 5. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
    Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL.
    J Clin Invest; 1998 Mar 01; 101(5):1084-93. PubMed ID: 9486979
    [Abstract] [Full Text] [Related]

  • 6. The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans.
    Goldberg IJ, Wagner WD, Pang L, Paka L, Curtiss LK, DeLozier JA, Shelness GS, Young CS, Pillarisetti S.
    J Biol Chem; 1998 Dec 25; 273(52):35355-61. PubMed ID: 9857078
    [Abstract] [Full Text] [Related]

  • 7. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
    Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, Ikeda M, Notoya M, Kamitani S, Arita H.
    J Biol Chem; 2002 Aug 09; 277(32):29116-24. PubMed ID: 12021277
    [Abstract] [Full Text] [Related]

  • 8. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E, Gautier T, Rosengren B, Dikkers A, Behrendt M, Grass DS, Rader DJ, Tietge UJ.
    Arterioscler Thromb Vasc Biol; 2013 Dec 09; 33(12):2707-14. PubMed ID: 24115030
    [Abstract] [Full Text] [Related]

  • 9. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation.
    Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, Webb NR.
    Arterioscler Thromb Vasc Biol; 2004 Apr 09; 24(4):762-7. PubMed ID: 14962950
    [Abstract] [Full Text] [Related]

  • 10. Immunoreactivity of apolipoprotein B-100 and binding to LDL-receptor of phospholipase A2-treated low density lipoproteins.
    Korotaeva AA, Golovanova NK, Vlasik TN, Yanushevskaya EV, Tsibulsky VP, Yakushkin VV, Tvorogova MG, Morozkin AD, Prokazova NV.
    Biochemistry (Mosc); 1998 Dec 09; 63(12):1430-7. PubMed ID: 9916162
    [Abstract] [Full Text] [Related]

  • 11. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans.
    Boyanovsky BB, van der Westhuyzen DR, Webb NR.
    J Biol Chem; 2005 Sep 23; 280(38):32746-52. PubMed ID: 16040605
    [Abstract] [Full Text] [Related]

  • 12. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
    Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG.
    J Clin Invest; 1998 Oct 15; 102(8):1559-68. PubMed ID: 9788969
    [Abstract] [Full Text] [Related]

  • 13. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100.
    Borén J, Ekström U, Agren B, Nilsson-Ehle P, Innerarity TL.
    J Biol Chem; 2001 Mar 23; 276(12):9214-8. PubMed ID: 11115503
    [Abstract] [Full Text] [Related]

  • 14. Phospholipase A2 and small, dense low-density lipoprotein.
    Hurt-Camejo E, Camejo G, Sartipy P.
    Curr Opin Lipidol; 2000 Oct 23; 11(5):465-71. PubMed ID: 11048889
    [Abstract] [Full Text] [Related]

  • 15. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy.
    Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, Tannock LR.
    Am J Pathol; 2011 Sep 23; 179(3):1179-87. PubMed ID: 21723246
    [Abstract] [Full Text] [Related]

  • 16. Proteolysis and fusion of low density lipoprotein particles strengthen their binding to human aortic proteoglycans.
    Paananen K, Saarinen J, Annila A, Kovanen PT.
    J Biol Chem; 1995 May 19; 270(20):12257-62. PubMed ID: 7744877
    [Abstract] [Full Text] [Related]

  • 17. Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen. Roles for both dimeric and monomeric forms of LPL.
    Pentikäinen MO, Oörni K, Kovanen PT.
    J Biol Chem; 2000 Feb 25; 275(8):5694-701. PubMed ID: 10681554
    [Abstract] [Full Text] [Related]

  • 18. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
    Olofsson SO, Borèn J.
    J Intern Med; 2005 Nov 25; 258(5):395-410. PubMed ID: 16238675
    [Abstract] [Full Text] [Related]

  • 19. Lipoprotein lipase-mediated interactions of small proteoglycans and low-density lipoproteins.
    Schönherr E, Zhao B, Hausser H, Müller M, Langer C, Wagner WD, Goldberg IJ, Kresse H.
    Eur J Cell Biol; 2000 Oct 25; 79(10):689-96. PubMed ID: 11089917
    [Abstract] [Full Text] [Related]

  • 20. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
    Ghesquiere SA, Gijbels MJ, Anthonsen M, van Gorp PJ, van der Made I, Johansen B, Hofker MH, de Winther MP.
    J Lipid Res; 2005 Feb 25; 46(2):201-10. PubMed ID: 15576846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.